Polar Capital’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Polar Capital’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-645,412	Closed	-$15.3M	–	317
2019 Q3	$15.3M	Buy	+645,412	New	+$19.1M	0.14%	165
2018 Q1	–	Sell	-125,000	Closed	-$1.06M	–	283
2017 Q4	$1.06M	Sell	125,000 -50,000	-29%	-$615K	0.01%	244
2017 Q3	$2.56M	Buy	175,000 +100,000	+133%	+$1.51M	0.03%	221
2017 Q2	$1.41M	Buy	+75,000	New	+$1.69M	0.02%	226

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital's RARX Position: Q4 2019 in Review

Polar Capital sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 645,412 shares — an estimated $15.3M sold.

Polar Capital first reported a position in RARX in Q2 2017 and held it in 4 quarters. The position peaked at $15.3M in Q3 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Polar Capital reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Polar Capital sold 645,412 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $15.3M.
Polar Capital first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
Polar Capital's Ra Pharmaceuticals, Inc. Common Stock position peaked at $15.3M in Q3 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Polar Capital's 13F filing for Q4 2019, filed 14 Feb 2020.